- Acceptance of Xceptol products on RangeMe website new revenue source, increasing SKUs and access to retailers
- RangeMe enables retail buyers to discover innovative, emerging products; empowers suppliers to manage, grow their brands
- CannAssist developed Xceptol brand to offer effective health and wellness solutions without side effects
CannAssist International (OTCQB: CNSC) has announced that its flagship brand — Xceptol — has been approved and included by the distribution website RangeMe (https://ibn.fm/c55wi). Xceptol’s inclusion on the website means increasing SKUs, access to more than 10,000 retailers, and a significant new revenue source for CNSC.
“This is exciting news for us on many fronts,” said CannAssist CEO Mark Palumbo. “A process estimated to take weeks was accomplished in a few days — a testament, I feel, to the quality of the Xceptol brand. Also gratifying is being included on the RangeMe website, a significant portal for major retailers to find products for their customers.”
RangeMe is an online platform that enables retail buyers to efficiently discover innovative and emerging products while empowering suppliers to manage and grow their brands with the tools, insights, and services they need. In the announcement, CNSC noted that RangeMe had added Xceptol drops and capsules to the Xceptol pain-cream products that are available on the RangeMe platform.
The inclusion brings the number of available Xceptol SKUs on RangeMe to 10, with additional SKUs coming in Q1 2021. RangeMe’s broad network creates a significant new revenue source for CannAssist International.
CannAssist developed its exclusive Xceptol brand, along with CiBiDinol or water-compatible cannabidiol, with the objective of offering powerful health and wellness solutions without troublesome side effects (https://ibn.fm/cdrAF). Team members had extensive experience and background with science, health care and conventional pharmaceutical therapies and recognized the need for a different approach to treatment of acute and chronic pain.
CannAssist experts began exploring ways to solve inherent issues with CBD delivery and bioavailability — CiBiDinol and the Xceptol brand are the result. Xceptol products feature CiBiDinol and offer better absorption than oil-based products currently available. CiBiDinol provides CBD in a format that is more in line with the body’s natural bioactivity and is specifically designed to tackle issues with oil-soluble CBD molecules, such as delivery, bioavailability and short shelf-life. Xceptol products also offer more predictable potency.
CNSC’s Xceptol Pain Cream is a CBD product with industry-defining reliability and compliance. Possessing a National Drug Code (“NDC”), the highest quality ingredients and the game-changing CiBiDinol, the pain cream is fast gaining attention in the pain-treatment space and is leading the way for other Xceptol products to follow. CannAssist believes Xceptol represents the next step for CBD products.
Established in 2017, CannAssist is headquartered in San Diego County, California, and is the owner of Xceptor Labs, a biotechnological pharmaceutical and wellness company. CannAssist is currently focused on marketing its Xceptol brand, which is why the RangeMe announcement is so significant.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC